首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Anti-hepatocellular carcinoma activity using human HepG2 cells and hepatotoxicity of 6-substituted methyl 3-aminothieno(3,2-b)pyridine-2-carboxylate derivatives: in vitro evaluation, cell cycle analysis and QSAR studies.
【24h】

Anti-hepatocellular carcinoma activity using human HepG2 cells and hepatotoxicity of 6-substituted methyl 3-aminothieno(3,2-b)pyridine-2-carboxylate derivatives: in vitro evaluation, cell cycle analysis and QSAR studies.

机译:使用人类HepG2细胞的抗肝细胞癌活性和6-取代的3-氨基硫代甲基(3,2-b)吡啶-2-羧酸甲酯衍生物的肝毒性:体外评估,细胞周期分析和QSAR研究。

获取原文
获取原文并翻译 | 示例
           

摘要

Hepatocellular carcinoma (HCC) is a highly complex cancer, resistant to commonly used treatments and new therapeutic agents are urgently needed. A total of thirty-two thieno[3,2-b]pyridine derivatives of two series: methyl 3-amino-6-(hetero)arylthieno[3,2-b]pyridine-2-carboxylates (1a-1t) and methyl 3-amino-6-[(hetero)arylethynyl]thieno[3,2-b]pyridine-2-carboxylates (2a-2n), previously prepared by some of us, were evaluated as new potential anti-HCC agents by studying their in vitro cell growth inhibition on human HepG2 cells and hepatotoxicity using a porcine liver primary cell culture (PLP1). The presence of amino groups linked to a benzene moiety emerges as the key element for the anti-HCC activity. The methyl 3-amino-6-[(3-aminophenyl)ethynyl]thieno[3,2-b]pyridine-2-carboxylate (2f) is the most potent compound presenting GI(50) values on HepG2 cells of 1.2 muM compared to 2.9 muM of the positive control ellipticine, with no observed hepatotoxicity (PLP1 GI(50) > 125 muM against 3.3 muM of ellipticine). Moreover this compound changes the cell cycle profile of the HepG2 cells, causing a decrease in the % of cells in the S phase and a cell cycle arrest in the G2/M phase. QSAR studies were also performed and the correlations obtained using molecular and 1D descriptors revealed the importance of the presence of amino groups and hydrogen bond donors for anti-HCC activity, and hydrogen bond acceptors for hepatotoxicity. The best correlations were obtained with 3D descriptors belonging to different subcategories for anti-HCC activity and hepatotoxicity, respectively. These results point to different molecular mechanisms of action of the compounds in anti-HCC activity and hepatotoxicity. This work presents some promising thieno[3,2-b]pyridine derivatives for potential use in the therapy of HCC. These compounds can also be used as scaffolds for further synthesis of more potent analogs.
机译:肝细胞癌(HCC)是一种高度复杂的癌症,对常用治疗具有抗药性,迫切需要新的治疗药物。总共两个系列的32种噻吩并[3,2-b]吡啶衍生物:3-氨基-6-(杂)芳基噻吩并[3,2-b]吡啶-2-羧酸甲酯(1a-1t)和甲基我们中的一些人先前制备的3-氨基-6-[(杂)芳基乙炔基]噻吩并[3,2-b]吡啶-2-羧酸酯(2a-2n)被研究为新的潜在抗HCC药物猪肝原代细胞培养(PLP1)对人HepG2细胞的体外细胞生长抑制和肝毒性。连接到苯部分的氨基的存在成为抗HCC活性的关键因素。 3-氨基-6-[[(3-氨基苯基)乙炔基]噻吩并[3,2-b]吡啶-2-羧酸甲酯(2f)是最有效的化合物,在HepG2细胞上显示的GI(50)值为1.2μM至2.9μM的阳性对照玫瑰树碱,未观察到肝毒性(针对3.3μM玫瑰树碱的PLP1 GI(50)> 125μM)。而且,该化合物改变了HepG2细胞的细胞周期概况,导致S期细胞百分比降低,而G2 / M期细胞周期停滞。还进行了QSAR研究,使用分子和1D描述符获得的相关性揭示了氨基和氢键供体对于抗HCC活性以及氢键受体对肝毒性的重要性。使用分别属于抗HCC活性和肝毒性的不同子类别的3D描述符获得了最佳相关性。这些结果表明了该化合物在抗HCC活性和肝毒性中的不同分子作用机理。这项工作提出了一些有希望的噻吩并[3,2-b]吡啶衍生物,可用于肝癌的治疗。这些化合物也可用作进一步合成更有效的类似物的支架。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号